Company intelligence / Profile preview

Healthpoint Biotherapeutics

Fort Worth, Texas, United Stateshealthpointchc.org ↗

Ownership: Private
Development stage: Commercial

Overview

Healthpoint’s lead candidate HP802‑247 demonstrated positive Phase 2b results for venous leg ulcer treatment, meeting both primary and secondary endpoints. The product entered Phase 3 trials prior to the company's acquisition. Marketed products such as Collagenase SANTYL Ointment, OASIS Wound Matrix family, and REGRANEX Gel were already commercialized at the time of acquisition.

Therapeutic areas: EndocrinologyCardiovascularDermatology
Modalities: Enzyme replacement therapyProteinCell therapyBiologic
Industry: Biotech

Drug pipeline

4 assets

HP-802-247

3 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Healthpoint Biotherapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Healthpoint Biotherapeutics.

Explore the full profile